Симптоматическое улучшение у больных раком легкого при лечении эрлотинибом (Тарцевой): анализ качества жизни в исследовании BR.21, проведенном Группой клинических исследований Национального института рака Канады

1. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8–29.
2. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589–97.
3. Gandara D, Chansky K, Albain K et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group study S9504. J Clin Oncol 2003; 21: 2004–10.
4. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials–Nonsmall Cell Lung Cancer Collaborative Group. BMJ 1995; 311: 899–909.
5. Shepherd FA, Dancey J, Ramlau R. et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095–103.
6. Fossella FV, DeVore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-smallcell lung cancer previously treated with platinumcontaining chemotherapy regimens: The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18: 2354–62.
7. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol: Classic Papers and Current Comments 2001; 6: 87–96.
8. Fukuoka M, Yano S, Giaccone G et al. Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced nonsmall-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21: 2237–46.
9. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003; 290: 2149–58.
10. Perez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non–small-cell lung cancer. J Clin Oncol 2004; 22: 3238–47.
11. Shepherd F, Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123–32.
12. Aaronson NK, Ahmedzai S, Bergman B et al. The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international trials in oncology. J Natl Cancer Inst 1993; 85: 365–76.
13. Bergman B, Aaronson NK, Ahmedzai S et al. The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQC30) for use in lung cancer clinical trials. Eur J Cancer 1994; 30A: 635–42.
14. Cull A, Sprangers M, Bjordal K et al. EORTC Quality of Life Group Translation Procedure. EORTC Quality of Life Group Publication, 2002.
15. Hopwood P, Stephens RJ. Symptoms at presentation for treatment in patients with lung cancer: Implications for the evaluation of palliative treatment – The Medical Research Council (MRC) Lung Cancer Working Party. Br J Cancer 1995; 71: 633–6.
16. Osoba D, Rodrigues G, Myles J et al. Interpreting the significant changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139–44.
17. Cella D, Eton D, Fairclough D et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) study 5592. J Clin Epidemiol 2002; 55: 285–95.
18. Hochberg Y. A sharp Bonferroni procedure for multiple tests of significance. Biometrics 1988; 75: 800–2.
19. Osoba D, Bezjak A, Brundage M. et al. Analysis and interpretation of health-related quality-oflife data from clinical trials: Basic approach of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2005; 41: 280–7.
20. Jansen SJ, Otten W, Stiggelbout AM. Review of determinants of patients’ preferences for adjuvant therapy in cancer. J Clin Oncol 2004; 22: 3181–90.
21. Koedoot CG, de Haan RJ, Stiggelbout AM et al. Palliative chemotherapy or best supportive care? A prospective study explaining patients’ treatment preference and choice. Br J Cancer 2003; 89: 2219–26.
22. Brundage MD, Davidson JR, Mackillop WJ. Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol 1997; 15: 330–40.
23. Brundage M, Leis A, Bezjak A et al. Cancer patients’ preferences for communicating clinical trial quality of life information: A qualitative study. Qual Life Res 2003; 12: 395–404.
24. Bezjak A, Ng P, Skeel R et al. Predicting oncologists’ use of quality-of-life (QOL) data: Results of a survey of Eastern Co-operative Group (ECOG) physicians. Qual Life Res 2001; 10: 1–13.
25. Detmar SB, Muller MJ, Schornagel JH et al. Role of health-related quality of life in palliative chemotherapy treatment decisions. J Clin Oncol 2002; 20: 1056–62.
26. Brundage M, Pater J, Zee B. Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data. J Natl Cancer Inst 1993; 85: 1138–48.
27. Butler L, Bacon M, Carey M et al. Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol 2004; 22: 2461–8.
28. Gridelli C, Gallo C, Shepherd F et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3025–34.
29. Anderson H, Hopwood P, Stephens RJ et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: A randomized trial with quality of life as the primary outcome – UK NSCLC Gemcitabine Group: Non-Small Cell Lung Cancer. Br J Cancer 2000; 83: 447–53.
30. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589–97.
31. Dancey J, Shepherd FA, Gralla RJ et al. Quality of life assessment of second-line docetaxel versus best supportive care in patients with nonsmall-cell lung cancer previously treated with platinum-based chemotherapy: Results of a prospective, randomized phase III trial. Lung Cancer 2004; 43: 183–94.

________________________________________________

A.Bezjak, Dongsheng Tu, L.Seymour, G.Clark, A.Trajkovic, M.Zukin, J.Ayoub, S.Lago, R. de Albuquerque Ribeiro, A.Gerogianni, A.Cyjon, J.Noble, F.Laberge, R.Tsz-Tong Chan, D.Fenton, J. von Pawel, M.Reck, F.A.Shepherd

Источник: The New England Journal of Medicine.